Xeris Pharmaceuticals is a pharmaceutical company. With technology platforms, XeriSol and XeriJect, that enable room-temperature stable formulations of injectable and infusible therapies, Co. is developing a portfolio of solutions in various therapeutic categories. Co.'s product, Gvoke®, delivers glucagon via a pre-filled syringe (Gvoke PFS) or auto-injector (Gvoke HypoPen®) for the treatment of severe hypoglycemia, a potentially life-threatening condition, in people with diabetes. The European Commission granted a marketing authorization for Ogluo® (glucagon) for the treatment of severe hypoglycemia in adults, adolescents, and children aged two years and over with diabetes mellitus. The XERS stock yearly return is shown above.
The yearly return on the XERS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the XERS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|